Evidence map›Paper›PMID 39966993›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025

Evaluating biparametric MRI for diagnosing muscle-invasive bladder cancer with variant urothelial histology: a multicenter study.

Peikun Liu, Lingkai Cai, Hongliang Que, Meihua Jiang, Xuping Jiang, Bo Liang, Gongcheng Wang, Linjing Jiang, Xiao Yang, Qiang Lu

Abstract readEvaluation StudyMulticenter Study
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Peikun Liu *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Lingkai Cai *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Hongliang Que *Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, 215000, China.
Meihua Jiang *Department of Radiology, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, 210029, China.
Xuping JiangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Bo LiangDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Gongcheng WangDepartment of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, China.
Linjing JiangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Xiao YangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. yangxiao2915@163.com.
Qiang LuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. doctorlvqiang@njmu.edu.cn.

Funding

Jiangsu Province Capability Improvement Project through Science, Technology and Education ZDXK202219Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University) Clinical Capacity Enhancement Project JSPH-MA-2022-5National Natural Science Foundation of China 82072832
6 · The paper itself

Abstract

backgroundVesical Imaging-Reporting and Data System (VI-RADS) based on multiparametric MRI (mp-MRI) demonstrated excellent performance in diagnosing muscle-invasive bladder cancer (MIBC) in cases of pure urothelial carcinoma. However, the performance of VI-RADS based on mp-MRI and biparametric MRI (bp-MRI) in diagnosing urothelial carcinoma with variant histology (VUC) remains unknown. PURPOSE: To evaluate the applicability of VI-RADS using mp-MRI and bp-MRI in diagnosing MIBC in patients with VUC.

methodsA retrospective analysis was conducted on 86 patients with VUC from different medical centers. Each patient underwent mp-MRI, with images evaluated using VI-RADS scores. The acquired images were divided into two groups: the mp-MRI group and the bp-MRI group. The mp-MRI group was evaluated according to the VI-RADS protocol. For the bp-MRI group, two VI-RADS scoring criteria were established: bp-DWI, primarily driven by DWI, and bp-T2WI, primarily driven by T2WI. The bp-MRI group was evaluated based on these two criteria. Inter-reader agreement performance was evaluated using Kappa analysis. The evaluation methods were evaluated by receiver operating characteristic curve. Comparison of the area under the curve (AUC) was performed used DeLong's test. A p-value < 0.05 was considered significant.

resultsInter-reader agreement was high across all evaluation methods, with Kappa values exceeding 0.80. The AUCs for mp-MRI, bp-DWI, and bp-T2WI were 0.934, 0.885, and 0.932, respectively. The diagnostic performance of bp-T2WI was comparable with that of mp-MRI (p = 0.682) and significantly higher than bp-DWI (p = 0.007). Both mp-MRI and bp-T2WI demonstrated high sensitivity and specificity.

conclusionVI-RADS based on mp-MRI demonstrates good diagnostic performance for MIBC in VUC patients. bp-T2WI may provide comparable diagnostic performance to mp-MRI.

Indexed as

Magnetic Resonance ImagingMultiparametric Magnetic Resonance ImagingUrinary Bladder NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm InvasivenessRetrospective StudiesBiparametric MRIDiagnostic performanceVariant histologyVesical imaging reporting and data system

Identifiers

PMID39966993
PMCPMC11834218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.